S-{2-[(3-aminopropyl){(1R)-1-[1-benzyl-4-(2,5-difluorophenyl)-1H-pyrrol-2-yl]-2,2-dimethylpropyl}amino]-2-oxoethyl}homocysteine;

4-amino-N-(3-aminopropyl)-N-{(1R)-1-[1-benzyl-4-(2,5-difluorophenyl)-1H-pyrrol-2-yl]-2,2-dimethylpropyl}benzamide;

4-[(2-{[(2R)-2-({(2S)-2-amino-4-[{(1R)-1-[1-benzyl-4-(2,5-difluorophenyl)-1H-pyrrol-2-yl]-2,2-dimethylpropyl}(glycoloyl)amino]butanoyl}amino)-2-carboxyethyl]amino}-2-oxoethyl)amino]-3-{[(2R)-2-amino-2-carboxyethyl]sulphanyl}-4-oxobutanoic acid;

4-[(2-{[(2R)-2-({(2S)-2-amino-4-[{(1R)-1-[1-benzyl-4-(2,5-difluorophenyl)-1H-pyrrol-2-yl]-2,2-dimethylpropyl}(glycoloyl)amino]butanoyl}amino)-2-carboxyethyl]amino}-2-oxoethyl)amino]-2-{[(2R)-2-amino-2-carboxyethyl]sulphonyl}-4-oxobutanoic acid.

62. Pharmaceutical composition comprising a conjugate according to one or more of Claims 1 to 43 or a compound according to Claims 48-61 in combination with an inert non-toxic pharmaceutically suitable auxiliary.

63. Conjugate according to one or more of Claims 1 to 43 or compound according to Claims 48-61 for use in a method for the treatment and/or prophylaxis of diseases.

64. Conjugate according to one or more of Claims 1 to 43 or compound according to Claims 48-61 for use in a method for the treatment of hyperproliferative and/or angiogenic disorders.

65. Conjugate according to one or more of Claims 1 to 43 or compound according to Claims 48-61 where R^{3a} or R^3 represents –L-BINDER or a substituted alkyl, aryl or heteroaryl group, preferably –L-#1 or a C_{1-10}-alkyl, C_{6-10}-aryl or C_{6-10}-aralkyl group or C_{5-10}-heteroalkyl, which may be substituted by –OH, O-alkyl, SH, S-alkyl, O-CO-alkyl, O-CO-NH-alkyl, NH-CO-alkyl, NH-CO-NH-alkyl, $S(O)_n$-alkyl, SO_2-NH-alkyl, NH-alkyl, $N(alkyl)_2$, NH_2 or $-(CH_2)_{0-3}Z$, where Z represents -H, halogen, $-OY^3$, $-SY^3$, $-NHY^3$, $-CO-NY^1Y^2$ or $-CO-OY^3$, where Y^1 and Y^2 independently of one another represent H, NH_2 or $-(CH_2)_{0-3}Z'$ and Y^3 represents H or $-(CH_2)_{0-3}Z'$, where Z' represents H, SO_3H, NH_2 or COOH,
(where "alkyl" preferably represents C_{1-10}-alkyl).

66. Method for the treatment and/or prophylaxis of hyperproliferative and/or angiogenic disorders in humans and animals using an effective amount of at least one conjugate according to one or more of Claims 1 to 43 or compound according to Claims 48-61.

67. Antibody conjugate according to one of the formulae below, where n is a number from 1 to 20 and AK_{1A} and AK_{2A} represent an antibody:

S-{2-[(3-aminopropyl){(1R)-1-[1-benzyl-4-(2,5-difluorophenyl)-1H-pyrrol-2-yl]-2,2-dimethylpropyl}amino]-2-oxoethyl}homocysteine;

4-amino-N-(3-aminopropyl)-N-{(1R)-1-[1-benzyl-4-(2,5-difluorophenyl)-1H-pyrrol-2-yl]-2,2-dimethylpropyl}benzamide;

4-[(2-{[(2R)-2-({(2S)-2-amino-4-[{(1R)-1-[1-benzyl-4-(2,5-difluorophenyl)-1H-pyrrol-2-yl]-2,2-dimethylpropyl}(glycoloyl)amino]butanoyl}amino)-2-carboxyethyl]amino}-2-oxoethyl)amino]-3-{[(2R)-2-amino-2-carboxyethyl]sulphanyl}-4-oxobutanoic acid;

4-[(2-{[(2R)-2-({(2S)-2-amino-4-[{(1R)-1-[1-benzyl-4-(2,5-difluorophenyl)-1H-pyrrol-2-yl]-2,2-dimethylpropyl}(glycoloyl)amino]butanoyl}amino)-2-carboxyethyl]amino}-2-oxoethyl)amino]-2-{[(2R)-2-amino-2-carboxyethyl]sulphonyl}-4-oxobutanoic acid.

62. Pharmaceutical composition comprising a conjugate according to one or more of Claims 1 to 43 or a compound according to Claims 48-61 in combination with an inert non-toxic pharmaceutically suitable auxiliary.

63. Conjugate according to one or more of Claims 1 to 43 or compound according to Claims 48-61 for use in the treatment and/or prophylaxis of diseases.

64. Conjugate according to one or more of Claims 1 to 43 or compound according to Claims 48-61 for use in the treatment of hyperproliferative and/or angiogenic disorders.

65. Conjugate according to one or more of Claims 1 to 43 or compound according to Claims 48-61 where R^{3a} or R^3 represents –L-BINDER or a substituted alkyl, aryl or heteroaryl group, preferably –L-#1 or a C_{1-10}-alkyl, C_{6-10}-aryl or C_{6-10}-aralkyl group or C_{5-10}-heteroalkyl, which may be substituted by –OH, O-alkyl, SH, S-alkyl, O-CO-alkyl, O-CO-NH-alkyl, NH-CO-alkyl, NH-CO-NH-alkyl, $S(O)_n$-alkyl, SO_2-NH-alkyl, NH-alkyl, $N(alkyl)_2$, NH_2 or $-(CH_2)_{0-3}Z$, where Z represents -H, halogen, $-OY^3$, $-SY^3$, $-NHY^3$, $-CO-NY^1Y^2$ or $-CO-OY^3$, where Y^1 and Y^2 independently of one another represent H, NH_2 or $-(CH_2)_{0-3}Z'$ and Y^3 represents H or $-(CH_2)_{0-3}Z'$, where Z' represents H, SO_3H, NH_2 or COOH,
(where "alkyl" preferably represents C_{1-10}-alkyl).

66. The use of at least one conjugate according to one or more of Claims 1 to 43 or compound according to Claims 48-61 in the manufacture of a medicament for the treatment and/or prophylaxis of hyperproliferative and/or angiogenic disorders.

67. Antibody conjugate according to one of the formulae below, where n is a number from 1 to 20 and AK_{1A} and AK_{2A} represent an antibody: